[go: up one dir, main page]

CR9516A - Formas solidas cristalinas y amorfas de halofenato (-)- y metodos relacionados a las mismas - Google Patents

Formas solidas cristalinas y amorfas de halofenato (-)- y metodos relacionados a las mismas

Info

Publication number
CR9516A
CR9516A CR9516A CR9516A CR9516A CR 9516 A CR9516 A CR 9516A CR 9516 A CR9516 A CR 9516A CR 9516 A CR9516 A CR 9516A CR 9516 A CR9516 A CR 9516A
Authority
CR
Costa Rica
Prior art keywords
halophenate
amorphes
same
crystal forms
methods related
Prior art date
Application number
CR9516A
Other languages
English (en)
Inventor
Edward D Daugs
Eric J Hagen
Jason A Hanko
David H Louks
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of CR9516A publication Critical patent/CR9516A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion proporciona formas solidas cristalinas y amorfas de halofenato (-). Las formas solidas cristalinas pueden utilizarse en diversas composiciones farmaceuticas y son particularmente efectivas para la prevencion y/o tratamiento de condiciones asociadas con la deposicion de lipidos en sangre en un mamifero, particularmente aquellas enfermedades relacionadas con diabetes Tipo 2 e hiperlipidemia.
CR9516A 2005-04-20 2007-11-13 Formas solidas cristalinas y amorfas de halofenato (-)- y metodos relacionados a las mismas CR9516A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67365505P 2005-04-20 2005-04-20

Publications (1)

Publication Number Publication Date
CR9516A true CR9516A (es) 2008-03-06

Family

ID=37115499

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9516A CR9516A (es) 2005-04-20 2007-11-13 Formas solidas cristalinas y amorfas de halofenato (-)- y metodos relacionados a las mismas

Country Status (15)

Country Link
US (5) US8203019B2 (es)
EP (1) EP1877362A1 (es)
JP (1) JP2008538570A (es)
KR (1) KR101372271B1 (es)
CN (1) CN101163660A (es)
BR (1) BRPI0610782A2 (es)
CA (1) CA2606279C (es)
CR (1) CR9516A (es)
EA (1) EA200702274A1 (es)
IL (1) IL186664A (es)
MX (1) MX2007012991A (es)
NO (1) NO20075831L (es)
UA (1) UA96571C2 (es)
WO (1) WO2006113917A1 (es)
ZA (1) ZA200709015B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8203019B2 (en) * 2005-04-20 2012-06-19 Metabolex, Inc. Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto
WO2009121940A1 (en) * 2008-04-03 2009-10-08 Janssen Pharmaceutica Nv Process for the preparation of (-)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester
US20230301919A1 (en) * 2020-09-03 2023-09-28 Philip Morris Products S.A. Freeze dried low hygroscopicity active powder compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953490A (en) 1972-07-13 1976-04-27 Merck & Co., Inc. Preparation of (3-trifluoromethylphenoxy)(4-chlorophenyl)acetonitrile
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US8203019B2 (en) * 2005-04-20 2012-06-19 Metabolex, Inc. Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto

Also Published As

Publication number Publication date
CN101163660A (zh) 2008-04-16
NO20075831L (no) 2008-01-18
US9845285B2 (en) 2017-12-19
IL186664A0 (en) 2008-01-20
US8203019B2 (en) 2012-06-19
US20160280636A1 (en) 2016-09-29
EP1877362A1 (en) 2008-01-16
CA2606279C (en) 2015-01-06
MX2007012991A (es) 2008-03-13
AU2006236153A1 (en) 2006-10-26
ZA200709015B (en) 2008-12-31
US20120232303A1 (en) 2012-09-13
CA2606279A1 (en) 2006-10-26
US20150225333A1 (en) 2015-08-13
JP2008538570A (ja) 2008-10-30
KR20070122567A (ko) 2007-12-31
KR101372271B1 (ko) 2014-03-17
WO2006113917A1 (en) 2006-10-26
US8993797B2 (en) 2015-03-31
WO2006113917A9 (en) 2008-02-14
US8507719B2 (en) 2013-08-13
US20080221018A1 (en) 2008-09-11
AU2006236153A2 (en) 2006-10-26
EA200702274A1 (ru) 2008-04-28
BRPI0610782A2 (pt) 2017-01-31
UA96571C2 (uk) 2011-11-25
US20140024852A1 (en) 2014-01-23
US9233914B2 (en) 2016-01-12
IL186664A (en) 2013-10-31

Similar Documents

Publication Publication Date Title
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
EP1876990A4 (en) DENTAL TREATMENT THROUGH ALIGNMENT ELEMENTS
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
BRPI0512944A (pt) agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
IL245387B (en) Medicament for use in the treatment of familial mediterranean fever comprising a human il-1 beta binding antibody
GT200500360A (es) Compuestos organicos
ATE488517T1 (de) 3 -amino- imidazo ä1,2-aüpyridinderivate mit sglt1 und sglt2 hemmender wirkung zur behandlung von diabetes vom typ 1 und typ 2
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
ATE476193T1 (de) Immunstimulatorisches verfahren
GT200600347A (es) Nueva formula cristalina iii de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
EP1965827A4 (en) TREATMENT OF CONDITIONS RELATED TO DEMYELINATION
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CR9516A (es) Formas solidas cristalinas y amorfas de halofenato (-)- y metodos relacionados a las mismas
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
ATE429222T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
PT1858481T (pt) Composições oftalmológicas e sua utilização
DE602006013945D1 (de) Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
PT1709082E (pt) Composição para tratamento de patologias associadas com srv/herv-w
ATE429221T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina

Legal Events

Date Code Title Description
FC Refusal